Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303682 | 0.74 | L3MBTL1 (0.54) | MAPTSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL6906186 | 0.73 | ALDH1A1 (0.47) | MAPTSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL8382659 | 0.73 | EPHX1 (0.52) | SMN1; SMN2NPC1RAB9ANFKB1KMT2A | |
| SCHEMBL4775488 | 0.73 | MAPT (0.44) | MAPTSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL5128756 | 0.72 | EPHX1 (0.50) | SMN1; SMN2NPC1RAB9AL3MBTL1MAPK1 | |
| SCHEMBL1383077 | 0.71 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL20594028 | 0.71 | L3MBTL1 (0.54) | MAPTSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL5622460 | 0.71 | EPHX1 (0.48) | SMN1; SMN2NPC1RAB9AL3MBTL1MAPK1 | |
| SCHEMBL18507224 | 0.71 | EPHX1 (0.48) | SMN1; SMN2NPC1RAB9AL3MBTL1MAPK1 | |
| SCHEMBL27813025 | 0.71 | EPHX1 (0.48) | SMN1; SMN2NPC1RAB9AL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1244636-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | Boehringer Ingelheim Pharma KG (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047896-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1095025-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001704-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | IL5, TSLP, TLR5 | MAPT 3961/4885SMN1; SMN2 3261/4885NPC1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.